Document Detail

Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature.
MedLine Citation:
PMID:  22746346     Owner:  NLM     Status:  Publisher    
Patients can develop malignancies due to various reasons including genetic factors, chemical carcinogens, radiation, and defects in their immune system. The immune system is postulated to carry out routine surveillance for malignancy. Patients who have defective immune responses may be susceptible to malignancies due to complicated underlying mechanisms. These include defective immune response to cancer-causing bacteria, transforming viruses, and other defects such as concomitant molecular, cellular and immunoregulatory defects. Common variable immune deficiency (CVID) is characterized by hypogammaglobulinemia, impaired antibody responses and an increased susceptibility to infections. A disorderly immune response, or immune dysregulation, may also lead to autoimmune complications and possibly to malignancy. The treatment of CVID involves infusion of replacement doses of immunoglobulin, either intravenously (IGIV) or subcutaneously (SCIG). However, it is unclear whether adequate replacement of immunoglobulins is sufficient to prevent the increased risk of malignancy seen in this disease. We present two cases of unusual solid tumors complicating CVID treated with adequate doses of intravenous immunoglobulins. In this study we review the occurrence of malignancy in patients with CVID and postulate mechanisms that may be involved indigent to this disease. We will also review the role of replacement immunoglobulin and discuss cancer screening in these high risk individuals.
C Watkins; R Sahni; N Holla; J Litchfield; G Youngberg; G Krishnaswamy
Related Documents :
25377646 - Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupu...
388946 - Fundamental studies on macrophage migration inhibitory factor(s) in the supernatant fro...
12538686 - In vivo blockade of macrophage migration inhibitory factor ameliorates acute experiment...
7704936 - Mif, a previously unrecognized pituitary hormone and macrophage cytokine, is a pivotal ...
19417146 - Topoisomerase ii{alpha}-dependent and -independent apoptotic effects of dexrazoxane and...
21148306 - The bh3 alpha-helical mimic bh3-m6 disrupts bcl-x(l), bcl-2, and mcl-1 protein-protein ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-29
Journal Detail:
Title:  Cardiovascular & hematological disorders drug targets     Volume:  -     ISSN:  2212-4063     ISO Abbreviation:  Cardiovasc Hematol Disord Drug Targets     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-7-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101269160     Medline TA:  Cardiovasc Hematol Disord Drug Targets     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Allergy and Immunology, PO Box 70622 Department of Medicine, Quillen College of Medicine , Johnson City, TN,USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of nicotine on ATPase, catalase and calcium levels in the presence of oligoelements in brain ...
Next Document:  A Meta-analysis of The Efficacy and Safety of Cilnidipine in Chinese Patients with Mild to Moderate ...